Skip to main content
Erschienen in: Current Treatment Options in Neurology 1/2011

01.02.2011 | Neurologic Ophthalmology and Otology

Herpes Zoster Ophthalmicus

verfasst von: Srinivasan Sanjay, MBBS, MRCS(Edin), MMed(Ophth), MS(Ophth), DNB(Ophth), Philemon Huang, MBBS, Raghavan Lavanya, MBBS, MRCS(Edin), DO

Erschienen in: Current Treatment Options in Neurology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Opinion statement

The management of herpes zoster (HZ) usually involves a multidisciplinary approach aiming to reduce complications and morbidity. Patients with herpes zoster ophthalmicus (HZO) are referred to ophthalmologists for prevention or treatment of its potential complications. Without prompt detection and treatment, HZO can lead to substantial visual disability. In our practice, we usually evaluate patients with HZO for corneal complications such as epithelial, stromal, and disciform keratitis; anterior uveitis; necrotizing retinitis; and cranial nerve palsies in relation to the eye. These are acute and usually sight-threatening. We recommend oral acyclovir in conjunction with topical 3% acyclovir ointment, lubricants, and steroids for conjunctival, corneal, and uveal inflammation associated with HZO. Persistent vasculitis and neuritis may result in chronic ocular complications, the most important of which are neurotrophic keratitis, mucus plaque keratitis, and lipid degeneration of corneal scars. Postherpetic complications, especially postherpetic neuralgia (PHN), are observed in well over half of patients with HZO. The severe, debilitating, chronic pain of PHN is treated locally with cold compresses and lidocaine cream (5%). These patients also receive systemic treatment with NSAIDs, and our medical colleagues cooperate in managing their depression and excruciating pain. Pain is the predominant symptom in all phases of HZ disease, being reported by up to 90% of patients. Ocular surgery for HZO-related complications is performed only after adequately stabilizing pre-existing ocular inflammation, raised intraocular pressure, dry eye, neurotrophic keratitis, and lagophthalmos. Cranial nerve palsies are common and most often involve the facial nerve, although palsy of the oculomotor, trochlear, and abducens nerves may occur in isolation or (rarely) simultaneously. In our setting, complete ophthalmoplegia is seen more often than isolated palsies, but recovery is usually complete. Vasculitis within the orbital apex (orbital apex syndrome) or brainstem dysfunction is postulated to be the cause of cranial nerve palsies. A vaccine of a lyophilized preparation of the oka strain of live, attenuated varicella-zoster virus is suggested for patients who are at risk of developing HZ and has been shown to boost immunity against HZ virus in older patients.
Literatur
1.
Zurück zum Zitat Edgerton AE: Herpes zoster ophthalmicus: report of cases and a review of the literature. Trans Am Ophthalmol Soc 1942, 40:390–439.PubMed Edgerton AE: Herpes zoster ophthalmicus: report of cases and a review of the literature. Trans Am Ophthalmol Soc 1942, 40:390–439.PubMed
2.
Zurück zum Zitat Zaal MJ, Volker-Dieben HJ, D’Amaro J: Prognostic value of Hutchinson’s sign in acute herpes zoster ophthalmicus. Graefes Arch Clin Exp Ophthalmol 2003, 241:187–191.CrossRefPubMed Zaal MJ, Volker-Dieben HJ, D’Amaro J: Prognostic value of Hutchinson’s sign in acute herpes zoster ophthalmicus. Graefes Arch Clin Exp Ophthalmol 2003, 241:187–191.CrossRefPubMed
3.
Zurück zum Zitat Kilgore PE, Kruszon-Moran D, Seward JF, et al.: Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003, 70(Suppl 1):S111–S118.CrossRefPubMed Kilgore PE, Kruszon-Moran D, Seward JF, et al.: Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003, 70(Suppl 1):S111–S118.CrossRefPubMed
4.
Zurück zum Zitat Harpaz R, Ortega-Sanchez IR, Seward JF: Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1–30.PubMed Harpaz R, Ortega-Sanchez IR, Seward JF: Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1–30.PubMed
5.
Zurück zum Zitat Liesegang TJ: Herpes zoster ophthalmicus: natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008, 115:S3–S12.CrossRefPubMed Liesegang TJ: Herpes zoster ophthalmicus: natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008, 115:S3–S12.CrossRefPubMed
6.
Zurück zum Zitat Yawn BP, Saddier P, Wollan P, et al.: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82:1341–1349.CrossRefPubMed Yawn BP, Saddier P, Wollan P, et al.: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82:1341–1349.CrossRefPubMed
7.
Zurück zum Zitat Scott FT, Johnson RW, Leedham-Green M, et al.: The burden of herpes zoster: a prospective population based study. Vaccine 2006, 24:1308–1314.CrossRefPubMed Scott FT, Johnson RW, Leedham-Green M, et al.: The burden of herpes zoster: a prospective population based study. Vaccine 2006, 24:1308–1314.CrossRefPubMed
8.
Zurück zum Zitat Dworkin RH, Johnson RW, Breuer J, et al.: Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44:S1–26.CrossRefPubMed Dworkin RH, Johnson RW, Breuer J, et al.: Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44:S1–26.CrossRefPubMed
9.
Zurück zum Zitat Oxman MN, Levin MJ, Johnson GR, et al.: Shingles Prevention Study Group: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271–2284.CrossRefPubMed Oxman MN, Levin MJ, Johnson GR, et al.: Shingles Prevention Study Group: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271–2284.CrossRefPubMed
10.
Zurück zum Zitat Cobo LM, Foulks GN, Liesegang T, et al.: Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986, 93:763–770.PubMed Cobo LM, Foulks GN, Liesegang T, et al.: Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986, 93:763–770.PubMed
11.
Zurück zum Zitat Severson EA, Baratz KH, Hodge DO, Burke JP: Herpes zoster ophthalmicus in Olmsted County, Minnesota: Have systemic antivirals made a difference? Arch Ophthalmol 2003, 121:386–390.PubMed Severson EA, Baratz KH, Hodge DO, Burke JP: Herpes zoster ophthalmicus in Olmsted County, Minnesota: Have systemic antivirals made a difference? Arch Ophthalmol 2003, 121:386–390.PubMed
12.
Zurück zum Zitat Wood MJ, Kay R, Dworkin RH, et al.: Oral acyclovir therapy accelerates pain resolution in patient with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996, 22:341–347.PubMed Wood MJ, Kay R, Dworkin RH, et al.: Oral acyclovir therapy accelerates pain resolution in patient with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996, 22:341–347.PubMed
13.
Zurück zum Zitat Shafran SD, Tyring SK, Ashton R, et al.: Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004, 29:248–253.CrossRefPubMed Shafran SD, Tyring SK, Ashton R, et al.: Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004, 29:248–253.CrossRefPubMed
14.
Zurück zum Zitat Tyring S, Barbarash RA, Nahlik JE, et al.: Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:89–96.PubMed Tyring S, Barbarash RA, Nahlik JE, et al.: Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:89–96.PubMed
15.
Zurück zum Zitat Colin J, Prisant O, Cochener B, et al.: Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000, 107:1507–1511.CrossRefPubMed Colin J, Prisant O, Cochener B, et al.: Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000, 107:1507–1511.CrossRefPubMed
16.
Zurück zum Zitat Tyring S, Engst R, Corriveau C, et al.: Collaborative Famciclovir Ophthalmic Zoster Research Group: Famciclovir for ophthalmic zoster: a randomized acyclovir controlled study. Br J Ophthalmol 2001, 85:576–594.CrossRefPubMed Tyring S, Engst R, Corriveau C, et al.: Collaborative Famciclovir Ophthalmic Zoster Research Group: Famciclovir for ophthalmic zoster: a randomized acyclovir controlled study. Br J Ophthalmol 2001, 85:576–594.CrossRefPubMed
17.
Zurück zum Zitat Leen CL, Mandal BK, Ellis ME, et al.: Acyclovir and pregnancy. Br Med J 1987, 294:308.CrossRef Leen CL, Mandal BK, Ellis ME, et al.: Acyclovir and pregnancy. Br Med J 1987, 294:308.CrossRef
18.
Zurück zum Zitat Pregnancy safety index. In Singapore MIMS 121st edition. Edited by Leong WF, Liza FE, Ruby DP, et al. Medical Information Management System (MIMS); 2010:A1–A13. Pregnancy safety index. In Singapore MIMS 121st edition. Edited by Leong WF, Liza FE, Ruby DP, et al. Medical Information Management System (MIMS); 2010:A1–A13.
19.
Zurück zum Zitat Pavan-Langston D: Herpes zoster antivirals and pain management. Ophthalmology 2008, 115(2 Suppl):S13–S20.CrossRefPubMed Pavan-Langston D: Herpes zoster antivirals and pain management. Ophthalmology 2008, 115(2 Suppl):S13–S20.CrossRefPubMed
20.
Zurück zum Zitat Ormrod D, Goa K: Valaciclovir: a review of its use in the management of herpes zoster. Drugs 2000, 59:1317–1340.CrossRefPubMed Ormrod D, Goa K: Valaciclovir: a review of its use in the management of herpes zoster. Drugs 2000, 59:1317–1340.CrossRefPubMed
21.
Zurück zum Zitat Gross G, Schofer H, Wassilew S, et al.: Herpes zoster guideline of German Dermatology Society (DDG). J Clin Virol 2003, 26:277–289.CrossRefPubMed Gross G, Schofer H, Wassilew S, et al.: Herpes zoster guideline of German Dermatology Society (DDG). J Clin Virol 2003, 26:277–289.CrossRefPubMed
22.
Zurück zum Zitat Engstrom Jr RE: Holland GN, Margolis TP, et al.: The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology 1994, 101:1488–1502.PubMed Engstrom Jr RE: Holland GN, Margolis TP, et al.: The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology 1994, 101:1488–1502.PubMed
23.
Zurück zum Zitat Purdy KW, Heckenlively JR, Church JA, et al.: Progressive outer retinal necrosis caused with varicella-zoster virus in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2003, 22:384–386.PubMed Purdy KW, Heckenlively JR, Church JA, et al.: Progressive outer retinal necrosis caused with varicella-zoster virus in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2003, 22:384–386.PubMed
24.
Zurück zum Zitat Wood MJ, Johnson RW, McKendrick MW, et al.: A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994, 330:896–900.CrossRefPubMed Wood MJ, Johnson RW, McKendrick MW, et al.: A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994, 330:896–900.CrossRefPubMed
25.
Zurück zum Zitat Whitley RJ, Weiss H, Gnann Jr JW: et al.: Acyclovir with and without prednisolone for the treatment of herpes zoster: a randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996, 125:376–383.PubMed Whitley RJ, Weiss H, Gnann Jr JW: et al.: Acyclovir with and without prednisolone for the treatment of herpes zoster: a randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996, 125:376–383.PubMed
27.
Zurück zum Zitat Watson CP, Babul N: Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998, 50:1837–1841.PubMed Watson CP, Babul N: Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998, 50:1837–1841.PubMed
28.
Zurück zum Zitat Boureau F, Legallicier P, Kabir-Ahmadi M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo controlled trial. Pain 2003, 104:323–331.CrossRefPubMed Boureau F, Legallicier P, Kabir-Ahmadi M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo controlled trial. Pain 2003, 104:323–331.CrossRefPubMed
29.
Zurück zum Zitat Watson CP, Vernich L, Chipman M, et al.: Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998, 51:1166–1171.PubMed Watson CP, Vernich L, Chipman M, et al.: Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998, 51:1166–1171.PubMed
30.
Zurück zum Zitat Raja SN, Haythornthwaite JA, Pappagallo M, et al.: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002, 59:1015–1021.PubMed Raja SN, Haythornthwaite JA, Pappagallo M, et al.: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002, 59:1015–1021.PubMed
31.
Zurück zum Zitat Rice ACS, Maton S: Gabapentin in postherpetic neuralgia: a randomized, double-blind, placebo controlled study. Pain 2001, 94:215–224.CrossRefPubMed Rice ACS, Maton S: Gabapentin in postherpetic neuralgia: a randomized, double-blind, placebo controlled study. Pain 2001, 94:215–224.CrossRefPubMed
32.
Zurück zum Zitat Frampton JE, Foster RH: Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005, 65:111–118; discussion 119–120.CrossRefPubMed Frampton JE, Foster RH: Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005, 65:111–118; discussion 119–120.CrossRefPubMed
33.
Zurück zum Zitat Kissin I, McDanal J, Xavier AV: Topical lidocaine for relief of superficial pain in postherpetic neuralgia. Neurology 1989, 39:1132–1133.PubMed Kissin I, McDanal J, Xavier AV: Topical lidocaine for relief of superficial pain in postherpetic neuralgia. Neurology 1989, 39:1132–1133.PubMed
34.
Zurück zum Zitat Stow PJ, Glynn CJ, Minor B: EMLA cream in the treatment of postherpetic neuralgia. Efficacy and pharmacokinetic profile. Pain 1989, 39:301–305.CrossRefPubMed Stow PJ, Glynn CJ, Minor B: EMLA cream in the treatment of postherpetic neuralgia. Efficacy and pharmacokinetic profile. Pain 1989, 39:301–305.CrossRefPubMed
35.
Zurück zum Zitat Watson CP, Tyler KL, Bickers DR, et al.: A randomized vehicle-controlled trial of topical capsaicin in the treatment of post herpetic neuralgia. Clin Ther 1993, 15:510–526.PubMed Watson CP, Tyler KL, Bickers DR, et al.: A randomized vehicle-controlled trial of topical capsaicin in the treatment of post herpetic neuralgia. Clin Ther 1993, 15:510–526.PubMed
36.
Zurück zum Zitat Davies PS, Galer BS: Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004, 64:937–947.CrossRefPubMed Davies PS, Galer BS: Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004, 64:937–947.CrossRefPubMed
37.
Zurück zum Zitat Vazquez M: Varicella zoster virus infections in children after the introduction of live attenuated varicella vaccine. Curr Opin Pediatr 2004, 16:80–84.CrossRefPubMed Vazquez M: Varicella zoster virus infections in children after the introduction of live attenuated varicella vaccine. Curr Opin Pediatr 2004, 16:80–84.CrossRefPubMed
38.
Zurück zum Zitat Zostavax prescribing information. Merck & Co.; Whitehouse Station, NJ: December 2009. Zostavax prescribing information. Merck & Co.; Whitehouse Station, NJ: December 2009.
39.
Zurück zum Zitat Lewith GT, Field J, Machin D: Acupuncture compared with placebo in postherpetic pain. Pain 1983, 17:361–368.CrossRefPubMed Lewith GT, Field J, Machin D: Acupuncture compared with placebo in postherpetic pain. Pain 1983, 17:361–368.CrossRefPubMed
40.
Zurück zum Zitat Kotani N, Kushikata T, Hashimoto H, et al.: Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000, 343:1514–1519.CrossRefPubMed Kotani N, Kushikata T, Hashimoto H, et al.: Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000, 343:1514–1519.CrossRefPubMed
41.
Zurück zum Zitat Yamada M, Ogata M, Kawai M, et al.: Substance P and its metabolites in normal human tears. Invest Ophthalmol Vis Sci 2002, 43:2622–2625.PubMed Yamada M, Ogata M, Kawai M, et al.: Substance P and its metabolites in normal human tears. Invest Ophthalmol Vis Sci 2002, 43:2622–2625.PubMed
42.
Zurück zum Zitat Yamada M, Ogata M, Kawai M, et al.: Decreased substance P concentrations in tears from patients with corneal hypoesthesia. Am J Ophthalmol 2000, 129:671–672.CrossRefPubMed Yamada M, Ogata M, Kawai M, et al.: Decreased substance P concentrations in tears from patients with corneal hypoesthesia. Am J Ophthalmol 2000, 129:671–672.CrossRefPubMed
43.
Zurück zum Zitat Nishida T, Nakamura M, Ofuji K, et al.: Synergistic effects of substance P with insulin-like growth factor-1 on corneal epithelial migration of the cornea. J Cell Physiol 1996, 169:159–166.CrossRefPubMed Nishida T, Nakamura M, Ofuji K, et al.: Synergistic effects of substance P with insulin-like growth factor-1 on corneal epithelial migration of the cornea. J Cell Physiol 1996, 169:159–166.CrossRefPubMed
44.
Zurück zum Zitat Nakamura M, Ofuji K, Chikama T, et al.: Combined effect of substance P and insulin-like growth factor-1 on corneal epithelial wound closure of rabbits in vivo. Curr Eye Res 1997, 16:275–278.CrossRefPubMed Nakamura M, Ofuji K, Chikama T, et al.: Combined effect of substance P and insulin-like growth factor-1 on corneal epithelial wound closure of rabbits in vivo. Curr Eye Res 1997, 16:275–278.CrossRefPubMed
45.•
Zurück zum Zitat Yamada N, Matsuda R, Morishige N, et al.: Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol 2008, 92:896–900.CrossRefPubMed Yamada N, Matsuda R, Morishige N, et al.: Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol 2008, 92:896–900.CrossRefPubMed
46.
Zurück zum Zitat Morishige N, Komatsubara T, Chikama T, et al.: Direct observation of corneal nerve fibres in neurotrophic keratopathy by confocal biomicroscopy. Lancet 1999, 354:1613–1614.CrossRefPubMed Morishige N, Komatsubara T, Chikama T, et al.: Direct observation of corneal nerve fibres in neurotrophic keratopathy by confocal biomicroscopy. Lancet 1999, 354:1613–1614.CrossRefPubMed
47.
Zurück zum Zitat Dunn SP, Heidemann DG, Chow CYC, et al.: Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4. Arch Ophthalmol 2010, 128:636–638.CrossRefPubMed Dunn SP, Heidemann DG, Chow CYC, et al.: Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4. Arch Ophthalmol 2010, 128:636–638.CrossRefPubMed
48.
Zurück zum Zitat Pavan-Langston D, Dohlman CH: Boston keratoprosthesis treatment of herpes zoster neurotrophic keratopathy. Ophthalmology 2008, 115:S21–S23.CrossRefPubMed Pavan-Langston D, Dohlman CH: Boston keratoprosthesis treatment of herpes zoster neurotrophic keratopathy. Ophthalmology 2008, 115:S21–S23.CrossRefPubMed
Metadaten
Titel
Herpes Zoster Ophthalmicus
verfasst von
Srinivasan Sanjay, MBBS, MRCS(Edin), MMed(Ophth), MS(Ophth), DNB(Ophth)
Philemon Huang, MBBS
Raghavan Lavanya, MBBS, MRCS(Edin), DO
Publikationsdatum
01.02.2011
Verlag
Current Science Inc.
Erschienen in
Current Treatment Options in Neurology / Ausgabe 1/2011
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-010-0098-1

Weitere Artikel der Ausgabe 1/2011

Current Treatment Options in Neurology 1/2011 Zur Ausgabe

Neurologic Ophthalmology and Otology

Fisher Syndrome

Neurologic Ophthalmology and Otology

Nonarteritic Anterior Ischemic Optic Neuropathy

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.